HCV direct-acting antiviral agents: The best interferon-free combinations

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 69-78

  Schinazi, Raymond ^a   Halfon, Philippe ^b   Marcellin, Patrick ^c   Asselah, Tarik ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Laboratoire Alphabio   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Asunaprevir; Daclatasvir; Faldaprevir; Pegylated interferon; Ribavirin; Simeprevir; Sofosbuvir

Indexed keywords

ABT 267; ABT 333; ABT 450 R; ABT 450R; ANTIVIRUS AGENT; ASUNAPREVIR; BMS 791325; DACLASTAVIR; DACLATASVIR; DIRECT ACTING ANTIVIRAL AGENT; FALDAPREVIR; LEDIPASVIR; MK 5172; MK 8742; NS5A INHIBITOR; NUCLEOSIDE ANALOG; POLYMERASE INHIBITOR; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; SERINE PROTEINASE; SOFOSBUVIR; UNCLASSIFIED DRUG; VIRUS MESSENGER RNA;

AMINO ACID SUBSTITUTION; ARTICLE; CELL CYCLE; COMPARATIVE STUDY; CROSS RESISTANCE; DRUG BINDING SITE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS REPLICATION; VIRUS RESISTANCE;

ASUNAPREVIR; DACLATASVIR; FALDAPREVIR; PEGYLATED INTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE ERADICATION; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; ISOQUINOLINES; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; SULFONAMIDES; THIAZOLES; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84890869379     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12423     Document Type: Article

References (41)

1. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-56.
2. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
3. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32: 88-102.
4. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-55.
5. Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4: 463-7.
6. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-25.
7. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in subjects with chronic hepatitis C. Gut 2008; 57: 516-24.
8. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
9. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Shortterm antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127: 1347-55.
10. Asselah T, Marcellin P. BILN 2061: a major step toward new therapeutic strategies in hepatitis C. J Hepatol 2004; 41: 178-81.
11. McCown MF, Rajyaguru S, Kular S, et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 2129-32.
12. Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 22619-28.
13. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials. AASLD 2013. Abstract 1122.
14. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. AASLD 2013. Abstract 1092.
15. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with peginterferon alfa-2a and ribivirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-54.
16. Sulkowski MS, Bourlière M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribivirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-63.
17. Jensen D, Asselah T, Dieterich D, et al. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment- naïve patients with chronic hepatitis C genotype-1 infection. AASLD 2013.
18. Jacobson I, Asselah T, Ferenci P, et al. STARTVerso3: a randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. AASLD 2013.
19. Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007; 7: 1302-29.
20. Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis 2011; 15: 627-39.
21. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
22. Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol 2011; 54: 1069-72.
23. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
24. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; 3: 527-32.
25. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
26. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047-55.
27. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.
28. Lalezari J, Holland L, Glutzer E, et al. Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir, and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection. AASLD 2013. 2013. Abstract LB-20.
29. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology 2012; 56(Suppl): LB1.
30. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.
31. Lawitz E, Hezode C, Varunok P, et al. Interferon- and Ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-naïve patients and prior null responders. AASLD 2013; 2013. Abstract 75.
32. Gane ED, Stedman CA, Hyland RH, et al. All-oral sofosbuvir-based 12-week regimes for the treatment of chronic HCV infection: the ELECTRON study. 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, 2013, Amsterdam, Netherlands; abstract 14.
33. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virological response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). 48th Annual Meeting of the EASL, April 24-28, 2013, Amsterdam, Netherlands; abstract 1417.
34. Everson GT, Sims KD, Thuluvath PJ, et al. Phase 2b study of the interferon-free and Ribavirin-free combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. AASLD 2013; Abstract 211.
35. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
36. Chayama K, Takahashi S, Toyota J, et al. AASLD 2013; Phase III study, with all-oral regimen of daclatasvir and asunaprevir achieved an overall SVR 84.7 percent in Japanese patients with chronic hepaptitis C (HCV) genotype 1b who were either interferon-ineligible/intolerant or non-responders to interferon-based ttherapies. AASLD 2013; Abstract 211.
37. Gane EJ, Ari ZB, Mollison L, et al. Efficacy and safety of an interferon-free regimen of MK-5172 + ribavirin for 12 weeks or 24 weeks in treatment naive, noncirrhotic subjects with HCV GT1 infection: the C-SPIRIT Study. AASLD 2013; Abstract 1110.
38. Jacobson JM, Ghalib RM, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 traetment-naive and prior null responder patients: the COSMOS study. AASLD 2013. Abstract LB-3.
39. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
40. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment option. N Engl J Med 2013; 368: 1867-77.
41. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2013; 15: 121-30.